MRI-Guided chemo reduction trial aims to spare TNBC patients from toxic drugs

This study tests whether MRI scans can identify triple-negative breast cancer patients who respond well to initial chemotherapy and immunotherapy, allowing them to skip the second, more toxic phase of treatment. About 54 participants will receive four cycles of a chemo-immunotherapy combo, then get an MRI. Those with a complete response on MRI will go straight to surgery, avoiding anthracycline drugs linked to heart problems and leukemia. The goal is to maintain high cure rates while reducing side effects.